PHILADELPHIA, PA — Last week, VintaBio presented promising new data at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting, spotlighting its proprietary VintaProcess™. This innovative platform addresses the challenges of manufacturing adeno-associated virus (AAV) vectors by delivering a compact, scalable solution with high yields and improved quality.
At the core of VintaProcess is a hyper-intensified, adherent, and perfusion-based system optimized for VintaBio’s proprietary HEK293 cell clone, VintaCell™, and the polymer-free transfection reagent, VintaFect™. Unlike traditional methods reliant on suspension cultures, VintaProcess uses a densely packed fixed-bed bioreactor, allowing cells to stay in their natural adherent state. This enables extended vector production lasting up to seven days post-transfection, significantly enhancing output and reducing impurities.
Key findings presented include:
- More than 8E14 total viral genomes can be produced in a hyper-intensified bioreactor smaller than a soda can. About 90% of this yield remains in the supernatant, reducing the need for cell lysis and host protein extraction.
- The process supports cellular activity for up to 12 days, ensuring longer, less toxic production cycles.
- Vector quality is significantly improved, with over 50% full capsids achievable by Day 3 of harvest and further improvements at Day 7, reducing downstream processing burdens.
“This study confirms that our VintaProcess platform enables a more natural, efficient, and scalable approach to AAV manufacturing,” said Junwei Sun, M.S., M.B.A., Co-founder of VintaBio. “By extending production time and leveraging our proprietary perfusion-based adherent culture technology, we can achieve high yields and quality with less processing complexity, ultimately offering better quality viral vectors for gene therapy developers.”
VintaProcess eliminates the need to push anchorage-dependent cells into suspension systems, reducing costly facility footprints. Its compact, benchtop design makes it an ideal choice for both clinical and commercial-scale manufacturing.
With its ability to enhance yields, improve scalability, and reduce impurities, VintaProcess offers a cost-effective and efficient pathway for advancing gene therapy manufacturing, paving the way for innovative treatments to reach patients faster.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.